Promising myeloma combo trial halted after just 4 patients
NCT ID NCT06163898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This very early study tested two drugs, alnuctamab and mezigdomide, together in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink tumors. However, the trial was stopped early after enrolling only 4 participants, so we have very little information about how well it worked or what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alnuctamab and mezigdomide (with dexamethasone)
What this could lead to
If it had succeeded, this combination could have offered a new treatment option for people with multiple myeloma that stopped responding to other therapies.
What could go wrong
The trial was terminated early with only 4 participants, so we have very little data. It is too early to know if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0018
New York, New York, 10065, United States
-
Local Institution - 0020
Jerusalem, 9112001, Israel
-
Local Institution - 0021
Petah Tikva, Central District, 4910021, Israel
-
Local Institution - 0030
Ramat Gan, Central District, 5262100, Israel
-
Local Institution - 0033
Birmingham, Alabama, 35294, United States
-
Local Institution - 0035
New Haven, Connecticut, 06511, United States